B A (B) patients without Carboplatin treatment (“INNSBRUCK” set) . Additional data file 8. Hazard Ratios for Relapse and Death. (A) Patients with Carboplatin treatment

Though categorization happens quickly, and at times stereotypically, it is not predictive for subsequent treatment of patients in a simple manner (if a, then b). The main

0 20 40 60 80 100 120 140 With pre-operative treatment Without pre-operative treatment With pre-operative treatment Without pre-operative treatment With pre-operative treatment

We report survival and treatment-related mortality (TRM) according to frailty status and treatment intensity from a large retrospective population-based study of patients with

Additionally, among prostate cancer patients treated with curative in- tention and patients receiving endocrine treatment a high prediagnostic diastolic BP ( ≥ 100 mmHg)

confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the subset of 63 Carboplatin treated ovarian

Cox-regression Hazard ratio (with 95% confidence intervals), likelihood ratio test P- value, and number of data values, for various predictive factors in the EUROPE set for full

Cox regression Hazard ratio (with 95% confidence intervals), likelihood ratio test P-value, and number of data values, for various predictive factors in the MAYO

Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with